Here’s Why KalVista Pharmaceuticals [NASDAQ: KALV] Stock Skyrocketing Today

Shares of KalVista Pharmaceuticals, Inc. [NASDAQ: KALV] touched the sky during the trading session of Tuesday. It has reported that KVD900 Phase 2 study has shown encouraging result which excited the stock of the firm. The clinical study has demonstrated that KVD900 is a useful and safe treatment for hereditary angioedema (HAE) attacks.

As compared to the current injectable treatments, KVD900 is the safest therapy for the patients and it is the biggest accomplishment of the company. The study showed that sufferers could take it when he/she is experiencing the attacks as it is the therapy which immediately provides the relief to the sufferers.

Shares of KalVista Pharmaceuticals, Inc. [NASDAQ: KALV] climbed 117.63% at $33.97 during the trading session of Tuesday. KALV has recorded a trading volume of 23.66 million as compared to the average volume of 124.75K. Its share has fluctuated between the 52-week low range of $5.61 and $20.21from its 52-week high. Its share has risen 435.24% and 48.42% during the 52-week low and high, respectively. This firm’s total market capitalization has remained high, reaching $270.52 million at the time of writing.

Furthermore, KVD900 Phase 2 study has been carried out to assess the safety and efficacy of KVD900 as a demanding cure for hereditary angioedema (HAE) attacks. The study has been carried out on 53 adult sufferers and the firm has divided the patients in type 1 and type 2 who got three attacks in 90 days before the registration.

In the first part of the two-part trial, sufferers have received a 600 mg dose of KVD900 to assess pharmacokinetic and pharmacodynamic properties. In the next part, all the sufferers have been entered into the study in which the safety and efficacy of KVD900 have been checked.

Phase II results have demonstrated that attacks treated with KVD900 substantially decreased the use of rescue. Almost 15% of KVD900 treated attacks rescued in comparison with the 30% on placebo at 12 hours. KVD900 substantially decreased the time to commencement of symptom aid. Additionally, in the trial sufferers have experienced no bad effects which proved that the study was successful.